Navigation Links
Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
Date:8/19/2007

- Planning for Phase 3 Trial Initiation on Track -

BRISBANE, Australia, Aug. 16 /PRNewswire-FirstCall/ -- Progen Pharmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) today announced it has executed an agreement with Quintiles, the world's largest Contract Research Organisation, to utilise their services for a number of clinical development- related projects. This agreement includes the execution of the Phase 3 clinical trial of anti-cancer drug PI-88 for the treatment of primary liver cancer (hepatocellular carcinoma).

Progen remains on track to initiate recruitment for the Phase 3 clinical trial in the fourth quarter of 2007. Quintiles operates directly in each of the 14 North American, European and Asian countries where Progen will be conducting the Phase 3 PI-88 trial.

"Quintiles has over 18,000 employees world-wide and has managed over 520 separate oncology studies. A number of these employees have been working with us as we prepare to initiate our Phase 3 trial in post-resection liver cancer. We have been consistently impressed with Quintiles's infrastructure in the regions where the trial will be conducted. They have already demonstrated to us that they have the communication and project management systems in place to successfully integrate key clinical operational procedures on the international level that this important trial requires," said Justus Homburg, Progen's CEO.

"Since the middle of last year, we have been working with external advisors, including Quintiles and the U.S. Food and Drug Administration (FDA), to develop our Phase 3 trial. We are aggressively pursuing the launch of this clinical trial on schedule and in parallel continue our discussions with the FDA on the SPA process," concluded Mr. Homburg.

The primary endpoint of the Phase 3 trial is the length of time patients remain disease-free (disease free survival or DFS) following surgery to remove tumour-affected parts of the liver. "Recent feedback from the FDA on our protocol has paved the way for DFS as the primary endpoint for the trial. Other key issues, including the selection of a sample size of 600 patients, have also been resolved. We are now finalising a few remaining aspects of the protocol's Statistical Analysis Plan for further review by the FDA. Critically, whilst we continue our dialogue with the FDA on specific details of the protocol, we are driving hard with Quintiles to launch this trial consistent with the target of starting patient enrolment before the end of this year," added Mr. Homburg.

About Progen: Progen Pharmaceuticals Limited is an Australian-based globally focused biotechnology company committed to the discovery, development and commercialisation of small molecule therapeutics primarily for the treatment of cancer.

About Quintiles: Quintiles Transnational Corp. is powering the next generation of healthcare by providing a broad range of professional services in drug development, financial partnering and commercialisation for the pharmaceutical, biotechnology and healthcare industries. With more than 18,000 employees and offices in more than 50 countries, it is focused on providing customer-centric solutions that are the gold standard of the industry. For more information, please visit the company's web site at http://www.quintiles.com.

Progen Information:

Justus Homburg

Progen Pharmaceuticals Limited

T: +61 7 3842 3333

E: justush@progen-pharma.com

Noreen Dillane

Progen Pharmaceuticals Limited

T: +61 7 3842 3333

E: noreend@progen-pharma.com

Media and Investor Relations Australia:

Rebecca Piercy

Buchan Consulting

T: +61 2 9237 2800 / +61 422 916 422

E: rpiercy@bcg.com.au

Rebecca Wilson

Buchan Consulting

T: +61 417 382 391

E: rwilson@bcg.com.au

Media Relations USA:

Robert D. Stanislaro

FD

T: +1 212 850 5657

E: robert.stanislaro@fd.com

Investor Relations USA:

Evan Smith

FD

T: +1 212 850 5606

E: evan.smith@fd.com


'/>"/>
SOURCE Progen Pharmaceuticals Limited

Copyright©2007 PR Newswire.

Related medicine technology :

1. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
2. Progenics Announces Positive Results in Clinical Trial of Novel HIV Therapy
3. Progens Phase 2 Liver Cancer Trial Exceeds Efficacy Objective
4. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
5. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
6. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
7. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... , Aug. 15, 2017 Diplomat Pharmacy, ... to Michigan residents. ... Flint retail pharmacy, G-3320 Beecher Road. ... by the Food and Drug Administration, is intended to ... drowsiness, slowed breathing, and loss of consciousness. The medication ...
(Date:8/11/2017)... 2017 DarioHealth Corp. (NASDAQ: DRIO), a leading ... data solutions, today announced that it will release its ... host a conference call at 9:00am ET. The Company ... results and its strategy and outlook for the remainder ... Erez Raphael , Chief Executive Officer, and Zvi ...
(Date:8/7/2017)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global ... Directors has approved the payment of a quarterly cash dividend ... The cash dividend of $0.24 per ... to stockholders of record as of the close of business ... to approval of the Board of Directors and may be ...
Breaking Medicine Technology:
(Date:8/16/2017)... ... August 16, 2017 , ... In a recent survey, eighty-two ... diet and exercise. In fact, cellulite can't always be eliminated by diet and exercise ... treatment available to select physicians nationwide. Dr. Kenneth Rothaus has recently added Cellulaze™ ...
(Date:8/16/2017)... ... 2017 , ... The Southeastern Telehealth Resource Center at the ... its funding from the Health Resources and Services Administration (HRSA), part of the ... time the HRSA administration has renewed its financial support to GPT since 2010 ...
(Date:8/16/2017)... ... August 16, 2017 , ... With a new PD diagnosis every ... cure. , The grants are awarded through a competitive application process and reviewed ... array of backgrounds and expertise in all areas relevant to PD research. The ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... based in Vero Beach, announced today that two of their associates were recognized ... represents professionally managed senior living communities in Florida. The awards were announced at ...
(Date:8/16/2017)... , ... August 16, 2017 , ... ... announces their latest new client win in the healthcare market, with Los Angeles-based ... to support healthcare staff and members. , AHF cares for nearly 800,000 individuals ...
Breaking Medicine News(10 mins):